PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price

PAVmed Inc.

Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.
Nasdaq granted additional 180-day extension until January 19, 2026 for 10 consecutive $1 closing bids.
Stock continues trading under PAVM; PAVmed says it will consider all available options.
Failure to cure during extension could lead to delisting from Nasdaq Capital Market.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.